kctLeShEjbmJRKrC

KYCO: Know Your Company

Reveal Profile

3 February 2026

1) Overview of the Company

Kenvue Inc. is the world’s largest pure-play consumer health company by revenue, operating as an independent publicly traded entity since May 2023 following its spin-off from Johnson & Johnson. The company is incorporated in Delaware and maintains its global headquarters in Summit, New Jersey, having relocated from its previous location in Skillman, New Jersey in March 2025. With $15.5 billion in net sales for 2024, Kenvue holds a unique position at the intersection of healthcare and consumer goods, combining the power of science with meaningful human insights and digital-first capabilities.

The company operates through three primary business segments: Self Care, Skin Health & Beauty, and Essential Health, serving approximately 1.2 billion people globally through a portfolio of iconic brands including Tylenol, Neutrogena, Listerine, Johnson’s, BAND-AID Brand, and Aveeno. These science-backed brands are recommended by healthcare professionals worldwide and have been trusted by consumers for generations. Kenvue’s products are sold and distributed in more than 165 countries, with approximately 50% of 2024 net sales generated outside North America, demonstrating the company’s well-balanced global footprint.

Kenvue trades on the New York Stock Exchange under the ticker symbol “KVUE” and employs approximately 22,000 people worldwide. The company’s strategic focus centers on profitable growth, durable cash flow generation, and disciplined capital allocation, supported by its “Our Vue Forward” restructuring initiative targeting $350 million in annualized cost savings by 2026. On November 3, 2025, Kimberly-Clark Corporation announced a definitive agreement to acquire all outstanding shares of Kenvue common stock in a cash and stock transaction valued at approximately $48.7 billion in enterprise value, with the transaction expected to close in the second half of 2026.

2) History

Kenvue Inc.’s origins trace back to Johnson & Johnson’s consumer health division, which had operated as part of the pharmaceutical giant for decades before the strategic decision was made to create an independent entity. On November 12, 2021, Johnson & Johnson announced its intention to spin off its consumer health business as a separate company, citing “a significant evolution in these markets, particularly on the consumer side” and the need to enable faster expansion for both businesses. This announcement occurred alongside similar strategic moves by other pharmaceutical companies, including Merck & Co.’s 2014 sale of its consumer health business to Bayer and Pfizer’s 2019 merger of its consumer health division with GSK’s consumer unit.

The consumer health business was formally registered as a Delaware corporation on February 23, 2022, under the provisional name JNTL, Inc., marking the legal foundation for what would become Kenvue. On September 28, 2022, Johnson & Johnson revealed that the new consumer health company would be called Kenvue, a name combining “ken,” a Scottish English word for ‘knowledge,’ and “vue,” a homophone of “view” intended to evoke the concept of ‘sight’. At this time, Kenvue’s workforce comprised approximately 22,000 employees worldwide.

Following the separation planning and preparation, Kenvue filed with the U.S. Securities and Exchange Commission for an initial public offering in January 2023. The IPO took place on May 4, 2023, with shares priced at $22 each, raising approximately $3.8 billion in capital and representing the largest U.S. IPO since November 2021. The offering implied an initial equity valuation of about $41 billion, with shares trading at $26.90 at the end of the first trading day. Johnson & Johnson initially retained almost 91 percent ownership after the IPO.

The complete separation from Johnson & Johnson was finalized through a share exchange in July 2023, and by August 2023, Kenvue was added to the S&P 500 Dividend Aristocrats index. The company was initially led by CEO Thibaut Mongon, who had extensive experience from his tenure at Johnson & Johnson. However, significant leadership changes occurred in July 2025 when Mongon departed the company and Kirk Perry was appointed as interim CEO, subsequently becoming permanent CEO in November 2025.

Throughout 2024 and 2025, Kenvue underwent substantial operational transformation as an independent company. The company successfully exited over 2,000 Transition Service Agreements across more than 50 countries without disruption to business operations, marking a critical milestone in establishing its autonomous operational capabilities. In March 2025, Kenvue relocated its global headquarters from Skillman, New Jersey to a new 290,000 square foot facility in Summit, New Jersey.

On November 3, 2025, Kimberly-Clark Corporation announced a definitive agreement to acquire all outstanding shares of Kenvue common stock in a cash and stock transaction valued at approximately $48.7 billion in enterprise value, with the transaction expected to close in the second half of 2026. This acquisition represents a significant milestone in Kenvue’s evolution, transforming it from an independent pure-play consumer health company into part of a larger global health and wellness organization.

3) Key Executives

Kirk Perry serves as Chief Executive Officer and Director of Kenvue, having been named to the permanent CEO role on November 2, 2025, after serving as Interim Chief Executive Officer since July 14, 2025. Perry brings over 30 years of global consumer-packaged goods, technology and business transformation experience, including 23 years with Procter & Gamble in roles of increasing responsibility such as President of Global Family Care and Vice President of U.S. Operations and North America Marketing. Prior to joining Kenvue’s Board of Directors in December 2024, Perry served as President and Chief Executive Officer of Circana, a global provider of technology, data and predictive analytics for the consumer, retail and media sectors, and previously held the position of President, Global Client and Agency Solutions at Google. He holds a B.B.A. from the University of Cincinnati and currently serves as a board member of The J.M. Smucker Company and Chick-Fil-A, Inc.

Amit Banati was appointed Chief Financial Officer effective May 12, 2025, bringing over 30 years of consumer products company finance and operations experience. He previously served as Vice Chairman and Chief Financial Officer at Kellanova (formerly Kellogg Company) from 2019-2022, where he led the business through significant transformation and implemented the company’s Deploy for Growth strategy. As Region President at Kellogg from 2012-2019, Banati more than doubled net sales and operating profit for the Asia, Middle East and Africa business. His earlier career included finance and general management roles at Kraft Foods, Cadbury Schweppes and Procter & Gamble, where he spent nearly 15 years in finance roles, rising to become Chief Financial Officer of the Asean, Australia, India, Singapore region in the Health and Beauty Care division. He holds a bachelor’s degree in commerce from Calcutta University and an MBA from the Indian Institute of Management in Lucknow, and currently serves on the Board of Fortune Brands Innovations.

Meri Stevens serves as Chief Operations Officer, leading end-to-end transformation to drive operational excellence, digitization and automation across Supply Chain, Procurement and Quality functions. Stevens brings over 30 years of operations experience through senior leadership positions at global corporations, having previously served as Johnson & Johnson Worldwide Vice President, Consumer Health Supply Chain & Delivery. Her extensive background includes serving as Chief Supply Chain Officer at Newell Rubbermaid and holding operations and procurement leadership roles at Tyco, Bertelsmann, Knoll and General Electric. She holds a B.S. in Mechanical and Electrical Engineering and a M.S. in Industrial Management from Rensselaer Polytechnic Institute, and serves as Vice Chair of the Smithsonian Science Education Center Advisory Board.

Matt Orlando serves as General Counsel for Kenvue, providing legal oversight and guidance across the company’s global operations. Orlando has been with the organization through its evolution as an independent company, supporting the complex legal and regulatory requirements associated with Kenvue’s separation from Johnson & Johnson and establishment as a standalone public company.

Luani Alvarado holds the position of Chief People Officer, leading the evolution of the company’s talent strategy and overseeing People Experience, Inclusion, Talent Development, Compensation, Health & Well-Being, HR Business Partners and Operations. She previously served as Global Leader, Human Resources for Johnson & Johnson Consumer Health and was a member of the Consumer Health Leadership Team and the Human Resources Executive Committee. Alvarado has over 15 years of experience at Johnson & Johnson in various leadership positions including Global Head of HR for Ethicon, Enterprise Chief Talent Officer, and Global Head of HR for Medical Devices, and prior to Johnson & Johnson, spent eight years at Bristol-Myers Squibb in Human Resources. She earned a Graduate degree in Human Resources & Strategic Management and a Bachelor of Science degree in Business Administration from Catholic University of Santos in Brazil.

Russell Dyer was appointed Chief Corporate Affairs Officer, bringing extensive communications and corporate affairs experience from his previous role as communications head at Mondelez International for over eight years. In his role at Kenvue, Dyer oversees the company’s corporate communications, public affairs, and stakeholder engagement strategies as the company continues to build its brand presence as an independent consumer health company.

Jonathan Halvorson was appointed to the newly created role of Chief Digital & Marketing Officer effective November 17, 2025, responsible for driving marketing excellence and transforming the company’s digital commerce strategy. Halvorson is a seasoned marketing and commercial leader who previously served as Senior Vice President of Consumer Experience and Digital Commerce at Mondelēz International, leading global teams driving digital marketing, AI adoption, and data-driven consumer engagement across brands like Cadbury, Oreo, Ritz, and Chips Ahoy. He holds a bachelor’s degree from the University of Missouri and an MBA from the University of Michigan.

Carlos De Jesus was appointed Group President, North America effective November 3, 2025, leading the fully integrated strategy and execution for Kenvue’s largest market. De Jesus brings over 25 years of experience in the global consumer products industry with a proven track record of driving growth for billion-dollar brands and leading large-scale turnarounds across global markets. He most recently served as Senior Vice President, Amazon Global Team Leader & North America Digital Commerce at Procter & Gamble, where he oversaw brands such as Pampers, Gillette, Duracell, Crest, and Oral-B. He holds a bachelor’s degree from Florida State University and an MBA from the University of Michigan.

Anindya Dasgupta serves as Group President, Asia Pacific, having joined Kenvue effective July 14, 2025, to lead the region that contributed approximately $3 billion in net sales in fiscal year 2024. Dasgupta brings nearly 30 years of consumer products experience, most recently serving as Chief Consumer Officer for Imperial Brands where he led product portfolio transformation. His career includes senior leadership roles at Fonterra, where he grew the consumer dairy business from $1.1 billion to $3.2 billion, nine years at PepsiCo culminating as Global Senior Director, Beverages leading the company’s $32 billion non-carbonated business, and various positions at GSK’s consumer goods division. He holds a bachelor’s degree in economics and statistics from Jadavpur University and a post-graduate degree in management from the Indian Institute of Management, Calcutta.

Michael Wondrasch was appointed Chief Technology & Data Officer effective August 25, 2025, responsible for enhancing Kenvue’s digital capabilities and driving technology-enabled growth. Wondrasch brings expertise in technology leadership and data strategy to support the company’s digital transformation initiatives and consumer engagement capabilities.

4) Ownership

Kenvue Inc. became a publicly traded company through a carefully orchestrated series of ownership transitions that began with its initial public offering on May 4, 2023, at $22 per share, raising approximately $3.8 billion. Upon completion of the IPO, Johnson & Johnson retained approximately 91.9% of Kenvue’s outstanding shares, with only about 10.4% of shares offered to the public. This initial structure positioned Kenvue as a controlled company under NYSE corporate governance rules due to Johnson & Johnson’s overwhelming voting control.

The most significant ownership transformation occurred through Johnson & Johnson’s strategic divestment process completed in two phases during 2023. In July 2023, Johnson & Johnson launched an exchange offer allowing its shareholders to exchange Johnson & Johnson common stock for Kenvue shares at a 7% discount. The oversubscribed exchange offer, which was 4.2 times subscribed, resulted in Johnson & Johnson accepting 190,955,436 shares of its own stock in exchange for 1,533,830,450 shares of Kenvue common stock on August 23, 2023. This transaction reduced Johnson & Johnson’s ownership to approximately 9.5% of Kenvue’s outstanding shares, marking Kenvue’s transition to a fully independent company.

Johnson & Johnson completed its exit from Kenvue through a debt-for-equity exchange in May 2024, transferring its remaining 182,329,550 shares (valued at approximately $3.75 billion) to Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC in exchange for Johnson & Johnson debt. This final divestment eliminated Johnson & Johnson’s ownership stake entirely and established Kenvue as a completely independent entity with no parent company control.

Currently, Kenvue’s ownership structure reflects that of a typical large-capitalization consumer goods company, with institutional investors holding approximately 99% of outstanding shares. The largest shareholders include The Vanguard Group Inc. with 12.26% ownership (234,951,484 shares), BlackRock Inc. with 7.56% (144,774,301 shares), T. Rowe Price Associates Inc. with 6.01% (115,083,065 shares), and State Street Corporation with 5.99% (114,801,877 shares). These institutional holdings demonstrate the broad distribution characteristic of widely-held public companies, with no single shareholder maintaining control.

The company’s governance structure has been influenced by activist investor engagement, particularly following Starboard Value LP’s acquisition of a stake representing approximately 1.15% of shares outstanding as of December 31, 2024. This activism culminated in a cooperation agreement in March 2025, resulting in Jeffrey Smith, Starboard’s CEO, joining Kenvue’s Board of Directors along with two additional independent directors. The agreement expanded the board temporarily from 11 to 14 directors, with plans to reduce to 13 directors following the 2025 Annual Meeting of Shareholders.

A transformative ownership change is pending through Kimberly-Clark Corporation’s announced acquisition of all outstanding Kenvue shares in a cash and stock transaction valued at approximately $48.7 billion in enterprise value. Under the merger agreement dated November 2, 2025, Kenvue shareholders will receive $3.50 per share in cash plus 0.14625 Kimberly-Clark shares for each Kenvue share held at closing, representing total consideration of $21.01 per share. Upon closing expected in the second half of 2026, current Kimberly-Clark shareholders will own approximately 54% of the combined company, while Kenvue shareholders will own approximately 46%. Both companies’ shareholders voted overwhelmingly to approve the transaction in January 2026, with approximately 96% of Kimberly-Clark shares and 99% of Kenvue shares voted in favor.

5) Financial Position

Kenvue Inc. trades on the New York Stock Exchange under the ticker symbol “KVUE” with a current stock price of $17.38 as of February 2, 2026. The company maintains a market capitalization of approximately $33.34 billion, with 1.92 billion shares outstanding and an average daily trading volume of 41.4 million shares. The stock has experienced significant volatility since its public listing, with a 52-week range from $14.02 to $25.17, representing the company’s lowest point reached on October 30, 2025, and its highest point achieved on May 8, 2025.

Over the past year, Kenvue’s stock performance has been challenging, declining 18.37% from February 2025 levels, though it has shown modest recovery of 0.75% year-to-date through February 2026. The stock reached an all-time high of $27.80 on May 15, 2023, shortly after its IPO, but has since declined 37.4% from that peak, reflecting investor concerns about the company’s transition as an independent entity and operational performance. The company’s current price-to-earnings ratio stands at 23.36, which is slightly below the Personal Products industry average of 25.06.

Kenvue’s profitability metrics demonstrate mixed performance trends over its independent operating period from 2023 through 2024. Full year 2024 net sales totaled $15.5 billion, representing a modest 0.1% increase from 2023 levels, with organic sales growth of 1.5% offset by foreign currency headwinds of 1.4%. However, diluted earnings per share declined to $0.54 in 2024 from $0.90 in 2023, reflecting a 40% decrease due to higher operational costs, increased brand investments, and separation-related expenses. Gross profit margin expanded significantly to 58.0% in 2024 from 56.0% in 2023, driven by productivity gains and value realization initiatives, though operating income margin contracted to 11.9% from 16.3% due to asset impairment charges and restructuring costs.

The company’s adjusted financial metrics provide insight into underlying operational performance excluding one-time items. Adjusted operating income margin was 21.5% in 2024 compared to 22.4% in 2023, while adjusted diluted earnings per share declined to $1.14 from $1.29, reflecting the impact of higher brand investments and public company costs that more than offset gross margin improvements. Free cash flow generation remained robust at $1.33 billion in 2024, though down from $2.70 billion in 2023, primarily due to working capital changes and higher capital expenditures.

Kenvue’s financial health indicators present areas of concern regarding liquidity and leverage. The company’s current ratio of 0.98 and quick ratio of 0.66 indicate potential short-term liquidity constraints, as current assets barely cover current liabilities. Total debt increased to $8.72 billion as of December 29, 2024, resulting in a debt-to-equity ratio of 85.66% and representing a significant leverage position inherited from the separation structure. Net debt-to-EBITDA ratio reached 2.28x in 2024, though S&P Global Ratings expects this to improve to approximately 2.0x by 2026 through debt repayment and earnings growth.

The consumer health industry faces several dynamic challenges that affect Kenvue’s financial outlook, including regulatory scrutiny of over-the-counter ingredients, private label competition, and evolving retail landscapes favoring e-commerce channels. Macroeconomic headwinds including foreign currency volatility, inflationary pressures, and potential tariff impacts are expected to create ongoing margin pressure, with management estimating approximately $150 million in gross tariff impact for 2025. Category growth rates have moderated, with seasonal businesses like cold and flu remedies experiencing weaker incidences, while the Skin Health & Beauty segment faces competitive pressures and execution challenges in key markets including the United States and China.

Key business risks disclosed by management include substantial indebtedness with restrictive covenants, exposure to product liability litigation particularly for talc-containing products sold outside the United States and Canada, and operational dependencies on transition service agreements with Johnson & Johnson that concluded in April 2025. The company also faces concentration risks from dependence on key retailers and distributors, with Walmart representing a significant customer relationship, while competitive dynamics in the consumer health space continue to intensify from both branded competitors and private label alternatives. Despite these challenges, the pending acquisition by Kimberly-Clark Corporation for approximately $48.7 billion in enterprise value, approved by shareholders in January 2026, provides a defined exit strategy expected to close in the second half of 2026.

6) Market Position

Kenvue Inc. operates as the world’s largest pure-play consumer health company by revenue, holding a dominant position across multiple categories within the global consumer health market valued at approximately $445 billion in 2022, with an expected compound annual growth rate of 4.5% through 2030. The company’s market leadership is anchored by 56 number one regional brand positions as of fiscal year 2024, including dominant positions in North America where brands like Nicorette command 48% market control, Listerine holds 45% market share, and BAND-AID Brand maintains 34% market share. This competitive strength is reinforced by the company’s extensive global reach, serving approximately 1.2 billion people daily across more than 165 countries, with international markets contributing approximately 50% of 2024 net sales.

The company’s strategic market positioning is built around three core business segments that collectively generated $15.5 billion in net sales during 2024. The Self Care segment accounts for approximately 42% of sales and includes pain care, cough and cold remedies, and allergy medications, where Kenvue maintains category leadership through brands like Tylenol, the number one global pain brand, and Zyrtec, the number one allergy brand globally. The Skin Health and Beauty segment represents 28% of sales, featuring dermatologically-focused brands including Neutrogena, the number one facial care brand in the United States and number three globally, alongside Aveeno, which holds the number three body care brand position globally. The Essential Health segment comprises 30% of sales and includes oral care leadership through Listerine, the number one mouthwash brand globally and five times larger than its closest competitor, as well as baby care dominance via Johnson’s Baby, the number one global baby toiletries brand.

Kenvue’s competitive differentiation stems from its unique positioning at the intersection of healthcare and consumer goods, leveraging science-backed formulations recommended by healthcare professionals. The company maintains relationships with over 80% of practicing dermatologists in the United States through its expanded sales force, while in the United Kingdom, it covers 6,000 additional pharmacists as of 2025. This professional endorsement strategy is supported by the company’s substantial research and development capabilities, including over 1,500 scientists who generated 561 new patents in 2024 alone, enabling the development of cutting-edge innovation and technology that reinforces brand credibility.

The company’s distribution network provides a significant competitive moat, with products available through mass retailers, pharmacies, and e-commerce channels worldwide. Kenvue operates 133 facilities globally for administration, research and development, manufacturing, warehousing, and distribution, including 12 sites in the United States and 121 sites across 58 other countries. The company’s omnichannel strategy has demonstrated strong performance, with e-commerce representing a growing portion of sales and achieving over 25% year-over-year growth in 2024, while direct-to-consumer channels offer significantly higher margins estimated at 60-65% compared to traditional retail.

Strategic positioning initiatives include substantial investments in marketing and brand activation, with advertising spend increasing to 10.6% of sales in 2024 from 8.7% in 2023, representing approximately $1.62 billion in total brand investment. This increased marketing focus emphasizes digital-first strategies, with 71% of marketing spend allocated to digital channels in 2022, up from 44% in 2019, supporting both online sales growth and in-store traffic generation. The company’s “Content Factory” marketing ecosystem enables production of breakthrough brand-building content across 40 markets, reducing time-to-market by 40% and enabling campaigns to move from brief to market in a matter of days.

Technology infrastructure represents another key competitive advantage, highlighted by Kenvue’s five-year collaboration with Microsoft announced in April 2025 to transform digital operations through advanced artificial intelligence technologies including predictive analytics, generative AI, and digital twins. This partnership aims to accelerate product development, optimize clinical research data, advance data-driven go-to-market strategies, and enhance omnichannel engagement while improving inventory management and reducing operational waste.

Operational capabilities include robust supply chain resilience demonstrated during the COVID-19 pandemic, when Kenvue experienced demand spikes of five to ten times pre-pandemic levels and sustained two-to-threefold demand increases across select brands. The company responded by building surge capacity internally, investing in partnership networks with suppliers and retailers, and creating real-time data capabilities that reduced forecast errors by more than 40% through machine learning and multivariate forecasting. Manufacturing efficiency initiatives have resulted in global supply chain optimization that contributed to 200 basis points of gross profit margin expansion in 2024, while the “Our Vue Forward” restructuring program targets $350 million in annualized cost savings by 2026.

Human capital metrics reflect the company’s transformation as an independent entity, with approximately one-third of the 22,000 global workforce representing new Kenvuers hired since the separation from Johnson & Johnson, bringing enhanced capabilities in marketing, sales, digital technology, and artificial intelligence across key markets. This talent influx supports the company’s innovation pipeline, which includes plans to launch 40% more innovations in 2025 compared to 2024, focusing on premiumization, category extensions, and attractive entry price points to strengthen market positioning and drive sustainable competitive advantages.

7) Legal Claims and Actions

Based on available information, Kenvue Inc. and its subsidiaries have maintained a relatively limited regulatory and legal claims profile since becoming an independent public company in May 2023. The company’s legal exposure has been significantly reduced compared to its former parent company Johnson & Johnson, as the separation agreement specifically excluded certain major litigation risks, particularly those related to talc-containing products sold in the United States and Canada.

The most recent legal matter involving Kenvue’s operations occurred on November 13, 2024, when Sirreon Goodson filed a lawsuit against Kenvue Brands LLC in the U.S. District Court for the Eastern District of California under case number 2:24-cv-03152. The complaint alleges “Torts – Personal Property – Other Fraud” under federal diversity jurisdiction (28 U.S.C. § 1332), though specific details regarding the nature of the alleged fraud, damages sought, or the underlying factual circumstances have not been disclosed in publicly available court records. Notably, Johnson & Johnson Services, Inc. was initially incorrectly named as a defendant in this action but was subsequently terminated from the case, reflecting the ongoing market confusion regarding the separation of Kenvue’s operations from its former parent company.

As of February 2026, no additional federal court litigation, regulatory enforcement actions, or criminal proceedings involving Kenvue Inc. or its subsidiaries have been identified in publicly available records. The company has not been subject to any SEC enforcement actions, CFTC sanctions, or other federal regulatory penalties since its independence. This limited legal claims profile contrasts with the extensive litigation history of Johnson & Johnson, from which Kenvue was specifically structured to be insulated through the separation agreement that allocated certain legacy liabilities to the pharmaceutical parent company rather than the consumer health spin-off.

The absence of significant regulatory enforcement activity reflects Kenvue’s focus on establishing robust compliance frameworks as a newly independent public company. The company has invested substantially in building standalone legal, compliance, and risk management capabilities, having successfully exited over 2,000 Transition Service Agreements with Johnson & Johnson across more than 50 countries without operational disruption. This systematic approach to compliance infrastructure appears to have supported the company’s ability to maintain regulatory compliance across its global operations during the complex transition period.

While the current legal claims profile appears manageable, Kenvue continues to face potential exposure to product liability litigation related to consumer health products sold outside the United States and Canada, as disclosed in the company’s 2024 Annual Report. The company maintains that it has adequate insurance coverage and legal reserves to address such contingencies, though the specific financial impact of any future claims cannot be predicted with certainty. The limited litigation exposure to date suggests effective risk management practices, though ongoing monitoring of product liability trends in international markets remains essential given the global reach of Kenvue’s consumer health product portfolio.

8) Recent Media

Kenvue’s recent media coverage has been dominated by its proposed acquisition by Kimberly-Clark, significant leadership changes, activist investor pressure, and numerous product-related legal and regulatory controversies. In November 2025, Kimberly-Clark announced a definitive agreement to acquire Kenvue in a cash-and-stock deal valued at an enterprise value of approximately $48.7 billion. The announcement was met with a mixed market reaction; Kenvue’s shares rose as much as 19.6%, while Kimberly-Clark’s stock dropped, with some market watchers suggesting Kimberly-Clark was “buying damaged goods” given Kenvue’s recent struggles. Morningstar analysts characterized the deal as a “hopeful exit ramp” for Kenvue shareholders. In January 2026, shareholders of both companies overwhelmingly approved the transaction, following a recommendation from proxy advisory firm Institutional Shareholder Services (ISS). The acquisition announcement followed media reports in June 2025 that Kenvue was exploring the sale of underperforming skin health brands such as Clean & Clear and Maui Moisture as part of a broader strategic review.

The company underwent significant leadership and governance shifts that garnered media attention. On July 14, 2025, Kenvue announced it had fired CEO Thibaut Mongon and appointed board member Kirk Perry as Interim CEO, a move media reports linked to the company’s underperformance and an ongoing strategic review. This executive change occurred amid intense pressure from activist investors. In October 2024, Starboard Value acquired a stake in the company to push for performance improvements, leading to a settlement in March 2025 that added Starboard’s CEO, Jeffrey Smith, and two other independent directors to Kenvue’s board. News also emerged in April 2025 that Daniel Loeb’s hedge fund Third Point had built a stake, and that activist firm Toms Capital was pushing for a sale of the company or its parts.

Kenvue has faced intense public scrutiny and legal challenges related to its products. In September 2025, the company’s stock dropped more than 10% after reports that U.S. Health and Human Services Secretary Robert F. Kennedy Jr. would release a report linking Tylenol’s active ingredient, acetaminophen, to autism when used during pregnancy. The controversy intensified when President Donald Trump publicly warned against the drug’s use, wiping out an estimated $10 billion in Kenvue’s market value and complicating its M&A prospects, according to media analysis. This was followed by a lawsuit filed by Texas Attorney General Ken Paxton on October 28, 2025, accusing Kenvue and Johnson & Johnson of deceptive marketing. Kenvue publicly refuted the claims as a “deliberate distortion of the facts being driven by the plaintiffs’ bar” and stated it would defend itself vigorously. Separately, after an FDA advisory panel concluded in September 2023 that the nasal decongestant phenylephrine was ineffective, a securities class-action lawsuit was filed against Kenvue, alleging it failed to disclose this risk in its IPO documents; a judge denied the company’s motion to dismiss the suit in March 2025.

Media outlets have also reported on legacy product liability issues and new product recalls. In October 2025, reports of the first U.K. lawsuits filed against Kenvue UK Limited and Johnson & Johnson concerning talc-based baby powder caused the stock to drop more than 13% in one day; under its spin-off agreement, Kenvue is responsible for talc liabilities outside the U.S. and Canada. In April 2024, a Chicago jury ordered Kenvue and Johnson & Johnson to pay $45 million to a family in a mesothelioma case, with Kenvue found to be 70% responsible. Additionally, in April 2024, Kenvue’s Benylin paediatric syrup was recalled in South Africa and other countries due to contamination with toxic diethylene glycol. In October 2025, the company voluntarily recalled certain lots of Neutrogena makeup wipes in four U.S. states because of bacterial contamination, a recall the FDA assigned a Class II risk level.

The company’s financial performance and operational restructuring have also been subjects of media coverage. Kenvue’s stock fell 5.8% in February 2024 after it missed Q4 2023 revenue estimates and issued soft guidance, with reports noting weakness in its U.S. skin and beauty segment. In May 2024, Kenvue announced a plan to cut 4% of its global workforce to achieve $350 million in annual savings by 2026. This followed earlier layoff announcements, including 57 positions in Pennsylvania in March 2023 and 69 at its new Summit, New Jersey headquarters in June 2025. In October 2025, Moody’s downgraded Kenvue’s outlook from “Stable” to “Negative,” citing operational headwinds and litigation risks. The company also faced legal action from the Texas Attorney General in December 2025 for failing to maintain proper business registration in the state, resulting in a court order to comply.

9) Strengths

World’s Largest Pure-Play Consumer Health Company by Revenue

Kenvue holds the distinction of being the world’s largest pure-play consumer health company by revenue, with $15.5 billion in net sales in 2024. This market leadership position provides significant competitive advantages through economies of scale, enhanced bargaining power with suppliers and retailers, and the ability to make substantial investments in research and development. The company’s pure-play focus allows for specialized expertise and dedicated resources entirely concentrated on consumer health categories, unlike diversified healthcare conglomerates.

Portfolio of Iconic and Market-Leading Brands

The company’s strength lies in its curated portfolio of iconic brands that hold dominant market positions across their respective categories. Kenvue maintains 37 number one positions in the categories and geographies where it competes, with ten of its brands generating over $400 million in net sales annually. These include Tylenol as the number one pain brand globally, Listerine as the number one mouthwash brand globally, Neutrogena as the number one facial care brand in the United States, and BAND-AID Brand as the number one adhesive bandage brand globally. This market leadership translates directly into pricing power, shelf space advantages, and sustained consumer loyalty.

Strong Scientific Heritage and Innovation Capabilities

Kenvue’s competitive advantage is reinforced by its robust scientific foundation, employing over 1,500 scientists who generated 561 new patents in 2024 alone. The company invests approximately $1.2 billion annually in research and development, representing a significant commitment to science-backed innovation. This scientific heritage enables the development of products with proven efficacy, supporting healthcare professional recommendations and consumer trust. The company’s products are backed by clinical studies and are recommended by healthcare professionals worldwide, creating a meaningful differentiation from competitors relying primarily on marketing rather than scientific substantiation.

Exceptional Global Reach and Distribution Network

The company operates in more than 165 countries with products reaching approximately 1.2 billion people daily, demonstrating unprecedented global scale and distribution capability. Kenvue maintains 133 facilities globally for administration, research and development, manufacturing, warehousing, and distribution, providing a comprehensive operational infrastructure. This global footprint is well-balanced geographically, with approximately 50% of 2024 net sales generated outside North America, reducing dependence on any single market and providing exposure to emerging market growth opportunities.

Strong Healthcare Professional Relationships and Credibility

Kenvue maintains exceptional relationships with healthcare professionals that serve as a significant competitive moat. The company’s expanded sales force reaches over 80% of practicing dermatologists in the United States, while in the United Kingdom it covers 6,000 additional pharmacists as of 2025. Many of the company’s brands operate as the number one recommended products by healthcare professionals in their respective categories and geographies, creating a powerful demand generation engine that competitors find difficult to replicate.

Robust Financial Performance and Cash Generation

The company demonstrates strong financial fundamentals with a gross profit margin of 58.0% in 2024, reflecting the pricing power of its premium brands and operational efficiency. Kenvue generates robust free cash flow of $1.33 billion in 2024, providing financial flexibility for brand investments, innovation, and shareholder returns. The company’s adjusted operating income margin of 21.5% in 2024 demonstrates effective cost management and the ability to maintain profitability while investing in growth initiatives.

Advanced Technology and Digital Transformation Capabilities

Kenvue has established a significant competitive advantage through its technology infrastructure and digital transformation initiatives. The five-year collaboration with Microsoft announced in April 2025 enables the integration of advanced artificial intelligence technologies including predictive analytics, generative AI, and digital twins across operations. The company’s “Content Factory” marketing ecosystem enables production of breakthrough brand-building content across 40 markets, reducing time-to-market by 40% and enabling campaigns to move from brief to market in a matter of days.

Proven Operational Resilience and Supply Chain Capabilities

The company has demonstrated exceptional operational resilience, successfully completing its separation from Johnson & Johnson by exiting over 2,000 Transition Service Agreements across more than 50 countries without business disruption. Kenvue’s supply chain demonstrated remarkable adaptability during the COVID-19 pandemic, handling demand spikes of five to ten times pre-pandemic levels and building surge capacity that reduced forecast errors by more than 40% through machine learning and multivariate forecasting.

Strong ESG Commitment and Sustainability Leadership

Kenvue has established a comprehensive sustainability framework through its “Healthy Lives Mission” focusing on Healthy People, Healthy Planet, and Healthy Practice. The company achieved a 37% reduction in operational emissions from its 2020 baseline by 2024 and expanded renewable electricity usage to 72% across global operations. Kenvue aims for 100% recyclable or refillable packaging by 2025 and has been recognized by Newsweek as one of America’s Most Responsible Companies for two consecutive years.

Fortune 500 Company Status and Industry Recognition

Kenvue’s debut on the Fortune 500 list at number 281 in 2025 validates its scale and market position as an independent company. The company has received prestigious recognition including two BIG Innovation Awards in 2025, with Chief Scientific Officer Caroline Tillett honored as a Visionary Leader and the Versalie digital platform recognized for addressing unmet consumer needs in women’s hormonal health. These accolades reinforce the company’s reputation for innovation excellence and industry leadership.

10) Potential Risk Areas for Further Diligence

Leadership Stability and Succession Risk

Kenvue faces significant leadership instability risks that warrant careful due diligence examination. The company terminated CEO Thibaut Mongon in July 2025 amid underperformance and appointed Kirk Perry as interim CEO before making the role permanent in November 2025. This executive transition occurred during a critical period when the company was undergoing activist investor pressure and strategic review processes. The departure of CFO Paul Ruh in May 2025, replaced by Amit Banati, further demonstrates turnover in key financial leadership positions. Additional leadership changes include the elimination of the Chief Growth Officer role and the departure of Group President Jan Meurer, raising concerns about organizational continuity and strategic execution capabilities during the company’s crucial transformation period as an independent entity.

Product Liability and Reputational Risk Concentration

The company faces substantial product liability risks that could significantly impact future operations and financial performance. Kenvue confronts over 500 lawsuits alleging Tylenol caused autism, with legal arguments scheduled for appellate review. The company also faces its first UK lawsuits over talc-containing products, representing over 3,000 claimants alleging cancer causation, for which Kenvue bears responsibility outside the United States and Canada under its separation agreement with Johnson & Johnson. High-profile political controversies, including statements by President Trump and Health Secretary Robert F. Kennedy Jr. linking Tylenol to autism during pregnancy, have created reputational challenges that resulted in stock price declines of over 10% in September 2025. The Texas Attorney General’s lawsuit filed in October 2025 alleging deceptive marketing practices regarding Tylenol’s safety profile adds regulatory enforcement risk to the litigation exposure.

Securities Fraud and IPO Disclosure Risk

Kenvue faces ongoing securities litigation challenging the adequacy of its IPO disclosures, with a federal court denying the company’s motion to dismiss class action claims in March 2025. The lawsuit alleges the company failed to disclose material risks regarding phenylephrine efficacy in its 2023 IPO documents, despite FDA investigations dating back to 2007 and an FDA advisory panel’s unanimous vote in September 2023 declaring oral phenylephrine ineffective as a nasal decongestant. Multiple shareholder complaints have also been filed in connection with the Kimberly-Clark acquisition, alleging material omissions in disclosure documents and seeking to enjoin shareholder votes. These securities fraud risks could result in significant financial settlements and ongoing legal costs while undermining investor confidence in management’s transparency and disclosure practices.

Financial Performance and Liquidity Concerns

The company’s financial metrics reveal concerning trends that require deeper analysis. Kenvue’s cash-to-assets ratio of 4.0% in Q3 2025 falls below the S&P 500 benchmark of 6.7%, indicating potential short-term liquidity constraints. Current ratio of 0.98 and quick ratio of 0.66 suggest that current assets barely cover current liabilities, creating working capital stress scenarios. Total debt increased to $8.9 billion in Q3 2025 from $8.286 billion previously, resulting in a debt-to-equity ratio of 20.6% and net debt-to-EBITDA ratio of 2.28x, requiring careful monitoring of covenant compliance and refinancing capabilities. The company’s three-year average revenue growth of 0.3% significantly underperforms the S&P 500’s 5.2%, while consecutive quarterly organic sales declines of 1.2%, 4.2%, and 4.4% in 2025 indicate structural challenges beyond temporary market conditions.

Regulatory Compliance and Product Efficacy Risk

Kenvue operates in a highly regulated environment where product efficacy challenges pose substantial business risks. The FDA’s determination that oral phenylephrine is ineffective as a nasal decongestant affects multiple Kenvue products and could require costly reformulation or market withdrawal. Regulatory scrutiny has intensified around acetaminophen safety during pregnancy, with FDA initiating label change processes following political pressure, potentially affecting Tylenol’s market position and requiring enhanced pharmacovigilance programs. The company also faces compliance risks related to state registration requirements, with Texas pursuing legal action for alleged failure to maintain proper business registration, highlighting potential regulatory gaps in multiple jurisdictions. Product recall risks remain elevated, as demonstrated by the 2024 recall of Neutrogena makeup wipes due to bacterial contamination and Benylin pediatric syrup recalls in international markets.

Activist Investor and Governance Pressure

The company faces ongoing activist investor pressure that could force strategic changes or operational disruptions. Starboard Value acquired a 1.15% stake and successfully gained board representation through a March 2025 settlement, adding three directors including CEO Jeffrey Smith. Additional activist involvement from Third Point and Toms Capital seeking portfolio sales or strategic alternatives creates multiple competing pressures on management strategy and capital allocation decisions. The cooperation agreement with Starboard is short-term and enables future proxy fights in advance of the 2026 shareholder meeting if performance targets are not met, creating ongoing governance uncertainty. Board composition changes, including the addition of five new independent directors in 2025, while strengthening independence, also create potential for competing strategic visions and execution challenges during the critical integration period with Kimberly-Clark.

Complex Organizational Structure and Integration Risk

As a relatively new independent company separated from Johnson & Johnson in 2023, Kenvue faces ongoing integration complexities that pose operational and strategic risks. The company successfully exited over 2,000 Transition Service Agreements but the establishment of standalone systems and processes remains incomplete, creating potential service disruptions and compliance gaps. The pending acquisition by Kimberly-Clark for $48.7 billion creates additional integration challenges, requiring successful merger of two distinct organizational cultures, operational systems, and brand portfolios. Approximately one-third of the workforce represents new employees hired since separation, requiring significant change management and cultural integration efforts while maintaining operational continuity. The relocation of headquarters from Skillman to Summit, New Jersey in March 2025 adds logistical complexity during an already transformational period.

Cybersecurity and Technology Infrastructure Vulnerabilities

Kenvue’s cybersecurity risk profile requires enhanced scrutiny given its global operations and recent separation from Johnson & Johnson’s technology infrastructure. The company maintains a formal cybersecurity program with annual training and employs automation and external consultants, but relies heavily on supply chain partners where cybersecurity incidents could materially impact operations. The five-year collaboration with Microsoft announced in April 2025 to implement advanced artificial intelligence technologies creates additional technology integration risks and potential security vulnerabilities during the transition period. As a newly independent company, Kenvue’s cybersecurity maturity may be less developed compared to established peers, while the complexity of managing global technology infrastructure across 165 countries creates multiple threat vectors requiring continuous monitoring and investment.

Standard Consumer Health Industry Considerations

The consumer health industry faces broad regulatory evolution as health authorities worldwide reassess over-the-counter ingredient safety and efficacy standards, potentially requiring costly product reformulations or market withdrawals across the industry. Macroeconomic pressures including inflation, currency volatility, and trade policy changes create ongoing margin pressure and supply chain disruption risks that affect all global consumer goods companies. The increasing competitive intensity from private label alternatives and direct-to-consumer brands in health and wellness categories threatens traditional branded product pricing power and market share across the sector.

Save as PDF